InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 -0.004 (-43.75%)+
Announcement
Release
12 Mar 2026 9:27AM
Price at Release
$0.008
Full Release
download
Summary
Osteopore Limited, an Australian-Singaporean leader in regenerative medicine, has secured non-exclusive distribution rights for an injectable regenerative bone filler from the biomedical division of dsm-firmenich. This agreement marks an expansion of Osteopore's orthopaedic product portfolio, enhancing its capability to treat orthopaedic bone defects with a minimally invasive approach. The product is designed to fill irregular-sized bone gaps, commonly encountered in trauma and reconstructive surgeries, providing a new revenue stream for the company. The agreement grants Osteopore distribution rights in the Southeast Asia region from 2026 to 2028, with product registration beginning in Singapore. This strategic move aligns with Osteopore's mission in regenerative medicine, optimizing sales channels in Singapore and throughout Southeast Asia.
Key Points
  • Osteopore Limited secures distribution rights from dsm-firmenich for injectable bone filler.
  • The product expands Osteopore's orthopaedic portfolio with minimally invasive treatment capabilities.
  • Distribution rights cover Southeast Asia for three years starting in 2026.
  • Osteopore will begin product registration in Singapore, with plans for regional expansion.
  • The agreement signifies increased market endorsement of Osteopore's commercial strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.